UNBS 5162

01/01/2017 - "However, the efficacy of UNBS5162 in human retinoblastomas is still not clear. "
01/01/2017 - "In the present study, we investigated the specific mechanism of UNBS5162 in the human retinoblastoma cell lines WERIRb1 and Y79. "
01/01/2017 - "Therefore, for the first time, we demonstrated that UNBS5162 can inhibit proliferation and promote apoptosis of human retinoblastoma cells by regulating activity of the Akt-mTOR pathway in vitro, suggesting the potential value of UNBS5162 in treatment for human retinoblastoma."
01/01/2017 - "The effects of UNBS5162 on human retinoblastoma cells may be regulated by the Akt-mTOR pathway. "
01/01/2017 - "UNBS5162 inhibits proliferation of human retinoblastoma cells by promoting cell apoptosis."

09/01/2018 - "In the present study, the effects of UNBS5162 on M14 human melanoma cells were evaluated by Cell Counting Kit‑8 and transwell assays, as well as western blotting. "
01/01/2019 - "These results reveal that UNBS5162 inhibits the cell activity of melanoma cells through the AKT/mTOR signaling pathway, and reverses epithelial-mesenchymal transition conversion in human melanoma cells. "
09/01/2018 - "UNBS5162 inhibits proliferation of human melanoma cells by inducing apoptosis via the PI3K/Akt pathway."
01/01/2019 - "This study on UNBS5162 and amonafide in melanomas provides an experimental basis of their uses and potential value on human melanoma treatment."
01/01/2019 - "After the treatment with UNBS5162 or amonafide, the migration of melanoma cells was inhibited in a dosede-pendent manner. "

10/01/2013 - "A Phase I study of UNBS5162 was conducted to establish pharmacokinetics (PK), maximum tolerated dose (MTD), dose-limiting toxicity, safety and anti-tumor activity in patients with advanced solid tumors or lymphoma. "
11/01/2018 - "UNBS5162 has been shown to have an anticancer effect in numerous cancer types, except triple negative breast cancer (TNBC). "
01/01/2017 - "UNBS5162, a naphthalimide, has broad prospects as a tumor treatment, with fewer toxic side effects and higher cancer-suppression efficiency. "
10/01/2013 - "Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma."
01/01/2019 - "UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway."

01/01/2018 - "These findings suggest that UNBS5162 could inhibit A549 cell proliferation and metastasis by inhibiting PI3K pathway mediated apoptosis."
01/01/2018 - "The present study demonstrated that UNBS5162 is a novel naphthalimide that may have potential therapeutic use for the prevention of esophageal cancer proliferation and metastasis via the PI3K/AKT signaling pathway."

10/01/2013 - "A Phase I study of UNBS5162 was conducted to establish pharmacokinetics (PK), maximum tolerated dose (MTD), dose-limiting toxicity, safety and anti-tumor activity in patients with advanced solid tumors or lymphoma. "
09/01/2018 - "Furthermore, UNBS5162 treatment led to decreased expression of the anti‑apoptotic protein B‑cell lymphoma 2, but increased expression of the pro‑apoptotic proteins Bcl‑2‑associated X protein and caspase‑3. "
10/01/2013 - "Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma."